rycarfa 20 mg tablets for dogs
krka, d.d., novo mesto - carprofen - tablet - 20 mg/tablet - carprofen - dogs - n.s.a.i.d.
rycarfa 50 mg tablets for dogs
krka, d.d., novo mesto - carprofen - tablet - 50 mg/tablet - carprofen - dogs - n.s.a.i.d.
vidalta 10 mg prolonged-release tablets for cats
intervet ireland limited - carbimazole - tablet - 10 mg/tablet - carbimazole - cats - hormone
vidalta 15 mg prolonged-release tablets for cats
intervet ireland limited - carbimazole - tablet - 15 mg/tablet - carbimazole - cats - hormone
apo-metformin xr 500 metformin hydrochloride 500 mg modified release tablet blister pack
arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: povidone; colloidal anhydrous silica; hypromellose; magnesium stearate - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.
apo-metformin xr 1000 metformin hydrochloride 1000 mg modified release tablet blister pack
arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: povidone; colloidal anhydrous silica; hypromellose; magnesium stearate - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.
blooms the chemist metformin xr 500 metformin hydrochloride 500 mg modified release tablet blister pack
gm pharma international pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: povidone; colloidal anhydrous silica; hypromellose; magnesium stearate - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.
blooms the chemist metformin xr 1000 metformin hydrochloride 1000 mg modified release tablet blister pack
gm pharma international pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: povidone; colloidal anhydrous silica; hypromellose; magnesium stearate - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.
aspen codeine codeine phosphate hemihydrate 30mg tablet blister pack
aspen pharmacare australia pty ltd - codeine phosphate hemihydrate, quantity: 30 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate - aspen codeine tablets are indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.
glyxambi 25 mg/5 mg empagliflozin/linagliptin 25mg/5mg film coated tablet blister pack
boehringer ingelheim pty ltd - linagliptin, quantity: 5 mg; empagliflozin, quantity: 25 mg - tablet, film coated - excipient ingredients: purified talc; hypromellose; mannitol; crospovidone; titanium dioxide; magnesium stearate; copovidone; pregelatinised maize starch; macrogol 6000; iron oxide red; maize starch - glyxambi tablets are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties ? clinical trials).